How Somatostatin Receptor 2 Controls Growth Hormone Feedback in the Brain | Research

The takeaway

Mice lacking the somatostatin receptor subtype 2 (SSTR2) lose the ability to respond to growth hormone negative feedback in the hypothalamus.

Complete loss of GH feedback
SSTR2 knockout mice showed zero negative feedback response to GH in arcuate nucleus neurons

What the researchers found

SSTR2 knockout mice showed no growth hormone negative feedback on arcuate nucleus neurons, demonstrating that this receptor subtype is essential for GH autoregulation.

Why it matters

Understanding the specific receptor responsible for GH feedback has direct implications for GH secretagogue therapy — drugs like GHRP and MK-677 work within this same regulatory system, and knowing which receptors control feedback helps predict and optimize therapeutic responses.

How the study worked

Knockout mouse model with genetic deletion of SSTR2, electrophysiological recording of arcuate nucleus neurons, and GH administration to test feedback responses.

What this study cannot tell us

Knockout models may have compensatory changes during development. Mouse GH physiology differs from humans in some respects. Only arcuate nucleus was studied — other brain regions also participate in GH regulation.

How to read the evidence

Well-designed knockout mouse study published in a respected endocrinology journal. Provides definitive evidence for SSTR2's role but limited to animal data.

When this study was published

Published in 1997, this study established SSTR2 as the key feedback receptor for GH — a finding that remains central to understanding GH regulation.

The bigger picture

GH release follows a pulsatile pattern controlled by the interplay of GHRH (stimulatory) and somatostatin (inhibitory). This study pinpoints SSTR2 as the critical brake on GH release. For peptide therapeutics like GHRPs that stimulate GH, understanding this feedback mechanism explains why timing and dosing patterns matter — the body's own regulatory system uses SSTR2 to prevent continuous GH elevation.

Questions still open

Do GH secretagogues like GHRP-6 partially overcome SSTR2-mediated feedback?
Could SSTR2 modulation enhance the effectiveness of GH-releasing peptides?
Are there age-related changes in SSTR2 expression that contribute to declining GH with aging?

Common questions

What is somatostatin and what does it do?

Somatostatin is a natural hormone that acts as a brake on growth hormone release. When GH levels get too high, somatostatin is released to slow down further production, keeping GH in a healthy pulsatile pattern.

Why does this matter for peptide therapies like GHRP?

GH-releasing peptides work partly by opposing somatostatin's inhibitory effects. Understanding that SSTR2 is the specific receptor controlling GH feedback helps explain how these peptides stimulate GH release and why the body naturally prevents excessive GH elevation.

Read the original research

Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons.

Molecular endocrinology (Baltimore, Md.), 11(11), 1709-17

View on PubMed ↗

Citation

Zheng, H; Bailey, A; Jiang, M H; Honda, K; Chen, H Y; Trumbauer, M E; Van der Ploeg, L H; Schaeffer, J M; Leng, G; Smith, R G. (1997). Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons.. Molecular endocrinology (Baltimore, Md.), 11(11), 1709-17.